Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial

BACKGROUND: Messenger RNA (mRNA)–1273 vaccine demonstrated 93.2% efficacy against coronavirus disease 2019 (COVID-19) in the Coronavirus Efficacy (COVE) trial. The humoral immunogenicity results are now reported. METHODS: Participants received 2 mRNA-1273 (100 µg) or placebo injections, 28 days apar...

Descripción completa

Detalles Bibliográficos
Autores principales: El Sahly, Hana M, Baden, Lindsey R, Essink, Brandon, Montefiori, David, McDermont, Adrian, Rupp, Richard, Lewis, Michael, Swaminathan, Shobha, Griffin, Carl, Fragoso, Veronica, Miller, Vicki E, Girard, Bethany, Paila, Yamuna D, Deng, Weiping, Tomassini, Joanne E, Paris, Robert, Schödel, Florian, Das, Rituparna, August, Allison, Leav, Brett, Miller, Jacqueline M, Zhou, Honghong, Pajon, Rolando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213865/
https://www.ncbi.nlm.nih.gov/pubmed/35535503
http://dx.doi.org/10.1093/infdis/jiac188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213865/
https://www.ncbi.nlm.nih.gov/pubmed/35535503
http://dx.doi.org/10.1093/infdis/jiac188

Ejemplares similares